Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+9.86%
-6.83%
+1.36%
-1.12%
-1.93%
CAPR
Capricor Therapeutics Inc
$8.26
Chart
$6.97 (+18.51%)
$13.18 (-37.33%)
$13.18 (-37.33%)
$4.81 (+71.73%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+9.86%
-6.83%
+1.36%
-1.12%
-1.93%
CAPR
Capricor Therapeutics Inc
Current Price
$8.26
Login to view Capricor Therapeutics Inc (CAPR) recommendation from the last 90 days from financial news and social media.
Chart
$6.97 (+18.51%)
$13.18 (-37.33%)
$13.18 (-37.33%)
$4.81 (+71.73%)
CAPR Latest Analysis
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy. Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases today announced positive four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel the Companys lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The dat
Today
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program. Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases today announced that the United States Food and Drug Administration (FDA) has granted to Deramiocel the companys lead cell therapy candidate for the potential treatment of Becker Muscular Dy
Tue Jun 17, 2025
Decoding Capricor Therapeuticss Options Activity: Whats the Big Picture?. High-rolling investors have positioned themselves bearish on Capricor Therapeutics (NASDAQ:) and it'.s important for retail traders to take note.\This activity came to our attention today through Benzinga'.s tracking of publicly available options data. The identities of these investors are uncertain but such a significant move in CAPR often signals that someone has privileged information.Today Benzinga'.s optio
Mon Jun 16, 2025
Capricor Therapeutics stock falls after FDA inspection of manufacturing facility.
Wed Jun 11, 2025
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program. Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases today announced the successful completion of the United States Food and Drug Administrations (FDA) Pre-License Inspection (PLI) of its San Diego manufacturing facility for Deramiocel the Companys lead cell therapy candidate with a Biologics L
Wed Jun 11, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CAPR Stock trends
CAPR Stock performance
CAPR Stock analysis
CAPR investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
